What is the appropriate outpatient treatment for an adult with an acute gout flare?

Outpatient Treatment for Acute Gout Flare

First-Line Treatment Options

For an acute gout flare, choose corticosteroids, NSAIDs, or colchicine as first-line therapy, with corticosteroids preferred when no contraindications exist due to superior safety profile and lower cost. 1

Corticosteroids (Preferred First-Line)

• Corticosteroids should be considered as first-line therapy because they are as effective as NSAIDs with fewer adverse effects and lower cost 1
• Prednisolone 35 mg daily for 5 days has been successfully used 1
• Intravenous or intramuscular corticosteroids may be the second-best option after canakinumab for pain reduction 2
• Contraindications include systemic fungal infections and known hypersensitivity 1
• Short-term adverse effects include dysphoria, mood disorders, elevated blood glucose, immune suppression, and fluid retention 1

NSAIDs (Alternative First-Line)

• All NSAIDs demonstrate similar efficacy—there is no evidence that indomethacin is superior to other NSAIDs despite common practice 1
• Acetic acid derivative NSAIDs (like indomethacin) may improve joint swelling and patient global assessment better than ibuprofen NSAIDs 2
• Main contraindications: renal disease, heart failure, cirrhosis 1
• Adverse effects include dyspepsia and risk of gastrointestinal perforations, ulcers, and bleeding 1

Colchicine (Alternative First-Line)

• Use low-dose colchicine regimen: 1.2 mg followed by 0.6 mg one hour later 1
• This low-dose regimen is as effective as higher doses (1.2 mg followed by 0.6 mg hourly for 6 hours) with significantly fewer gastrointestinal adverse effects 1
• Colchicine is currently the most expensive non-biologic option 1
• Contraindicated in patients with renal or hepatic impairment using potent CYP3A4 inhibitors or P-glycoprotein inhibitors 1
• Common adverse effects: diarrhea (23% with low-dose vs 77% with high-dose), nausea, vomiting, cramps 1

Advanced Therapies

Canakinumab (IL-1β Inhibitor)

• Provides the highest pain reduction at day 2 and longest follow-up compared to all other interventions 2
• Reserved for patients refractory to or with contraindications to NSAIDs and/or colchicine 3
• Not recommended as first-line due to cost and availability 3

Urate-Lowering Therapy During Acute Flare

You can start urate-lowering therapy during an acute gout flare rather than waiting for resolution 1

• Starting ULT during a flare does not significantly extend flare duration or severity 1
• This approach offers time efficiency and capitalizes on patient motivation during symptomatic periods 1
• Must provide concomitant anti-inflammatory prophylaxis when initiating ULT 1

Anti-Inflammatory Prophylaxis Protocol

• Strongly recommend prophylaxis for 3-6 months rather than less than 3 months when starting ULT 1
• Use colchicine, NSAIDs, or low-dose corticosteroids for prophylaxis 1
• Continue prophylaxis with ongoing evaluation; extend if patient continues experiencing flares 1
• Expect increased gout flares in the 3 months immediately after stopping prophylaxis (29.7% vs 14.7% during prophylaxis), which then return to baseline levels 4

Common Pitfalls to Avoid

• Do not use high-dose colchicine regimens—they offer no additional benefit and cause significantly more gastrointestinal adverse effects 1
• Do not delay ULT initiation in patients with recurrent gout (≥2 episodes per year) or problematic gout (tophi, chronic kidney disease, urolithiasis) 1
• Do not start long-term ULT after a first gout attack or with infrequent attacks (<2 per year) 1
• Do not assume indomethacin is superior to other NSAIDs—moderate-quality evidence shows no clinically important differences between different NSAIDs 1